Microsulis Medical has received the US Food and Drug Administration 510(k) clearance to market Acculis Accu2i percutaneous microwave tissue ablation (pMTA) system for the coagulation of soft tissue during surgical procedures.
Microsulis said that the treatment allows physicians to apply precise microwave energy to ablate unwanted tissue masses.
The system has already been in use in Europe treating liver and lung tumors via a small 1.8mm needle puncture of the skin.
According to Microsulis Medical Acculis Accu2i pMTA system is a high power 2.45 GHz system that enables larger and faster ablations to be performed and the ablative therapy will be available as an option for many more patients.
Microsulis Medical CEO Stuart McIntyre said that they are looking forward to introducing the pMTA product to the US market after seeing its success throughout Europe.